Delivery Order SPE2DB20D2104-SPE2DB23FS93R
- Not listed
- This federal contract award between the Defense Logistics Agency (DLA) and Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a pharmaceutical product. The contract, valued at $1,633.92, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of $999,999,999.00 and runs through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to...
- This federal contract award, valued at $1,790.07, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a pharmaceutical product, to support military healthcare programs. The contract is a Firm Fixed Price Delivery Order with no set-aside designation, indicating full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award, valued at $6,094.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a pharmaceutical product. The award has a completion date of February 5, 2024 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,279.30 firm fixed-price delivery order is for the supply of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a pharmaceutical product. The award has an ultimate completion date of May 3, 2023. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award, valued at $2,034.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for NOVOLOG 100 UNIT/ML FLEXPEN 3ML medical supplies. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for...
- This federal contract award, valued at $1,724.59, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a critical medical product. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,733.85 firm-fixed-price delivery order is for the supply of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a medical product, to support the U.S. government's healthcare needs. The contract has an ultimate completion date of December 7, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,128.14 firm fixed-price delivery order is for the supply of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a medical commodity used in the treatment of diabetes. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with...
- This federal contract award is a delivery order worth $2,110.59 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML medical supplies. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award, valued at $2,625.81, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a medical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FS93RDelivery Order
This federal contract award, valued at $2,723.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of NOVOLOG 100 UNIT/ML FLEXPEN 3ML, a pharmaceutical product. The award is a delivery order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a broad range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. This contract does not have a set-aside designation, indicating full and open competition. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that has a significant role in supplying medical products to federal government agencies, particularly the Department of Defense and Department of Veterans Affairs. The company's extensive federal contract awards demonstrate its capacity to efficiently fulfill government requirements for essential pharmaceutical and medical commodities across multiple therapeutic areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 4/5/23 |